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Abstract Streptococcus pneumoniae and Staphylococcus
aureus cause significant morbidity and mortality worldwide.
We investigated both the colonization and co-colonization
characteristics for these pathogens among 250 healthy
children from 2 to 5 years of age in Merida, Venezuela, in
2007. The prevalence of S. pneumoniae colonization, S.
aureus colonization, and S. pneumoniae–S. aureus co-
colonization was 28%, 56%, and 16%, respectively. Pneumo-
coccal serotypes 6B (14%), 19F (12%), 23F (12%), 15 (9%),
6A (8%), 11 (8%), 23A (6%), and 34 (6%) were the most
prevalent. Non-respiratory atopy was a risk factor for S. aureus
colonization (p=0.017). Vaccine serotypes were negatively
associated with preceding respiratory infection (p=0.02) and
with S. aureus colonization (p=0.03). We observed a high
prevalence of pneumococcal resistance against trimethoprim–
sulfamethoxazole (40%), erythromycin (38%), and penicillin
(14%). Semi-quantitative measurement of pneumococcal
colonization density showed that children with young siblings
and low socioeconomic status were more densely colonized
(p=0.02andp=0.02, respectively). In contrast, trimethoprim–
sulfamethoxazole- and multidrug-resistant-pneumococci colo-
nized children sparsely (p=0.03 and p=0.01, respectively).
Our data form an important basis to monitor the future impact
of pneumococcal vaccination on bacterial colonization, as
well as to recommend a rationalized and restrictive anti-
microbial use in our community.
Introduction
Streptococcus pneumoniae is one of the major pathogens
infecting humans worldwide. It is the most common cause
of community-acquired bacterial pneumonia and otitis
media, but can also give rise to severe cases of meningitis
and sepsis. It is estimated that 1.6 million people die from
pneumococcal diseases every year [1]. Despite causing
severe diseases, S. pneumoniae is also asymptomatically
carried in the nose, nasopharynx, and throat. In children,
the isolation rates of S. pneumoniae obtained by nasal and
nasopharyngeal sampling are similar, but higher than by
oropharyngeal sampling [2, 3]. The prevalence of S.
pneumoniae nasopharyngeal colonization varies from 7 to
99%, depending on the age, health, and socioeconomic
status of the study population [4].
Although there are currently over 90 distinct serotypes,
certain serotypes commonly account for the majority of
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distribution of serotypes is temporal and varies according
to geographic location. The serotype distribution among
carriage isolates is often used as an indicator for theoretical
vaccine coverage [4]. Several clinical and demographic
characteristics have been positively associated with an
increase in S. pneumoniae colonization, such as young
age, crowding, day care attendance, family size, number of
siblings, poverty, smoking, and recent antibiotic use [4, 5].
In particular, the worldwide rise of pneumococcal anti-
biotic resistance is alarming and represents a threat for the
successful treatment of infections caused by this pathogen
[6, 7].
Staphylococcus aureus is a frequent cause of clinically
relevant diseases, ranging from relatively mild infections
such as skin infections and otitis media, to life-threatening
invasive infections such as pneumonia, bacteremia, and
endocarditis. S. aureus is also asymptomatically carried on
the skin, in the perineum, nose, and nasopharynx. Although
multiple body sites can be colonized, S. aureus is most
frequently carried in the anterior nares of the nose. S. aureus
iscarriedbyapproximately30%ofhealthyadultsand10%of
children [8, 9]. Older siblings, family size, breast-feeding,
and passive smoking have been suggested to influence the
S. aureus carriage rate in healthy children [9, 10]. Moreover,
several studies have shown increased S. aureus nasal
colonization among patients with respiratory and non-
respiratory allergies compared to the general population
[11, 12]. In addition, symptomatic allergic rhinitis leads to
an increase in the airborne dispersal of S. aureus [13, 14].
Epidemiological studies monitoring the carriage of S.
pneumoniae and S. aureus are important for several
reasons. First, colonization in healthy individuals is a
prerequisite for developing invasive and non-invasive dis-
eases, and reduced colonization has been correlated with
decreased pneumococcal and staphylococcal infection
rates [4, 15]. Second, healthy carriers serve as reservoirs
for S. aureus and S. pneumoniae transmission to others in
the community and in the hospital [8–10]. And third,
carriage strains have been used as indicators for drug
resistance, and for pneumococcal serotype distribution and
vaccine coverage prediction [6].
Bacterial colonization is also the result of interspecies
competition, and some bacterial species are either positively
or negatively associatedduringco-colonization. For instance,
several epidemiologic studies have reported a negative
association between S. pneumoniae nasopharyngeal coloni-
zation and S. aureus nasal colonization, which was most
significant for S. pneumoniae serotypes included in the 7-
valent pneumococcal conjugate vaccine [10, 16, 17].
However, the epidemiology of co-colonization for these
pathogens in the same ecological niche, i.e., the nose of
healthy children, has not been investigated in detail.
The importance of S. pneumoniae carriage surveillance
in Latin American countries is underlined by the significant
contribution of this pathogen to pediatric morbidity and
mortality. The population of Latin America in 2007 was 565
million[18], and the estimated annual burden of pneumonia,
meningitis, and otitis media caused by S. pneumoniae in
children under 5 years of age are in the ranges 980,000–
1,500,000, 2,600–6,800, and 980,000–1,500,000, respec-
tively [1]. Even though an estimated 12,000 to 28,000
deaths due to pneumococcal disease occur in the region
annually, infant pneumococcal vaccination is not a routine
part of the current immunization programs in any of the
countries in Latin America [1].
Information regarding the distribution of pneumococcal
serotypes, as well as clinical and demographic characteristics
associated with S. aureus and S. pneumoniae colonization,
are important for the design and monitoring of strategies to
prevent and control these infections [4, 15]. However, in
Venezuela, data regarding the serotype distribution and
prevalence of S. pneumoniae colonization and epidemio-
logical records of nasal colonization of S. aureus in healthy
children is scarce [19].
The objective of this study was to investigate in detail
the microbiological, clinical, and demographic features
associated with S. pneumoniae and S. aureus nasal
colonization and co-colonization among healthy Venezuelan
children.
Materials and methods
Study population
All children enrolled in this study were sampled in January
and February 2007 in five schools in Merida, Venezuela.
Criteria for inclusion were age under 5 years, absence of
pneumococcal vaccination, and no current respiratory
infection (RI). To avoid the inclusion of children with
possible current RI, we excluded children showing symp-
toms or signs of RI, as well as those who received at least
one dose of any antibiotic treatment during the previous
15 days. One of the children’s parents signed informed
consent and provided clinical and demographic informa-
tion, such as age, sex, crowding (i.e., two or more people
sleeping in the same room), siblings, smokers at home, and
socioeconomic status. In addition, we asked whether the
children also attended a day care center when they were not
at school. Detailed medical information was recorded, such
as previous diagnosis of atopies, asthma, allergic rhinitis
and non-respiratory atopies, history of hospitalization in the
previous 6 months, and antibiotic treatment in the previous
3 months. Incidence and history of previous RIs were also
recorded in detail. The study was reviewed and approved
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Humanistic and Technological Development (CDCHT) of
the Los Andes University (Mérida, Venezuela).
Sample collection
Mucus specimens from both nares of the child were
obtained using a sterile cotton-tipped swab. Swabs were
plated immediately onto brain heart infusion agar plates
with 5% blood and 4 μg/ml of gentamycin, and onto
mannitol salt agar plates (Oxoid®, Badhoevedorp, The
Netherlands) by rolling the swab over one-quarter of the
plate and streaking the sample onto four quadrants using a
sterile loop as previously described [20]. Blood agar plates
and mannitol agar plates were then incubated at 35°C under
microaerophilic and aerobic conditions, respectively.
Bacterial isolation, identification, and serotyping
S. pneumoniae was identified by Gram stain, colony
characteristics, susceptibility to optochin, and bile solubility.
Pneumococcal serotypes were determined by the capsular
reaction test (Quellung reaction) using specific antisera
(Statens Serum Institut, Copenhagen, Denmark). Six strains
were not available for serotyping. For the serogroups 10, 11,
and 15, antiserum for subtyping was not available. All
pneumococcal Quelling-non-typeable strains were reinvesti-
gated for the presence of the most common pneumococcal
serotypes using a multiplex polymerase chain reaction
(PCR) assay as described previously [21]. Additionally, for
all 6A serotypes and non-typeable strains, we determined
by PCR the presence of wciN6C of serotype 6C as
described previously [22]. The 6C capsular type was
confirmed by Dr. Moon Nahm (University of Alabama,
Birmingham, AL, USA) using 6C-specific monoclonal
anticapsule antibodies (Hyp6AM3) as previously described
[23]. Those serotypes included in the heptavalent pneumo-
coccal polysaccharide conjugate vaccine (Prevenar®, Wyeth
Pharmaceuticals, Philadelphia, PA, USA) were considered as
vaccine serotypes. S. aureus was identified by Gram stain,
colony characteristics, and biochemical conventional tests.
Susceptibility testing
S. pneumoniae susceptibility and minimal inhibitory con-
centrations (MICs) for 19 antimicrobial drugs were deter-
mined following the recommendations of the Clinical and
Laboratory Standards Institute (CLSI) guidelines [24]. Six
S. pneumoniae strains were not available for susceptibility
testing. For all MIC testing, S. pneumoniae ATCC 49619
was included as a quality control strain. The agar dilution
method was performed to determine penicillin susceptibility
using Penicillin G (Calbiochem®, Merck, Darmstadt,
Germany) and Mueller–Hinton II agar (BBL Microbiology
Systems, Cockeysville, MD, USA) supplemented with
5% sheep blood. For the other 18 antimicrobials, we used
a commercial microdilution panel (Sensititre® STP5F-
Streptococcus pneumoniae MIC plate, TREK Diagnostic
Systems, East Grinstead, UK) containing cefepime, cefo-
taxime, ceftriaxone, cefuroxime, clindamycin, daptomycin,
erythromycin, ertapenem, levofloxacin, linezolid, meropenem,
moxifloxacin, chloramphenicol, tigecycline, tetracycline, teli-
thromycin, trimethoprim–sulfamethoxazole, and vancomycin.
We used Mueller–Hinton agar supplemented with lysed
horseblood broth (CP112-10, TREK Diagnostic Systems, East
Grinstead, UK) as the test medium. The MIC breakpoints
suggested by the current CLSI 2009 document were used for
all antimicrobials tested. In the case of penicillin and
cefuroxime, we used the breakpoints suggested for oral
treatment (penicillin: S: susceptible, ≤ 0.06 μg / m l ;I :i n t e r m e -
diate, 0.12–1 μg / m l ;R :r e s i s t a n t ,≥2 μg/ml; and cefuroxime:
S, ≤1 μg/ml; I, 2 μg/ml; R, ≥4 μg/ml). For the other
cephalosporins, i.e., cefotaxime, ceftriaxone and cefepime,
the breakpoints suggested for non-meningitis were used
(S:≤1 μg / m l ;I :2μg/ml; R:≥4 μg/ml). We considered
strains being non-susceptible to three or more different
classes of antimicrobials as multidrug-resistant (MDR).
Colonization density of S. pneumoniae
We used the number of colony forming units (CFUs) in
S. pneumoniae-positive cultures as an indicator for coloni-
zation density. All S. pneumoniae-positive cultures were
checked after 20–24 h of incubation, and the CFUs were
counted by the same operator. CFUs were scored using a
semi-quantitative scale by O’Brien et al. [20] as follows:
scant growth: < 25 CFUs in quadrant 1; 1+ growth: ≥ 25
CFUs in quadrant 1 and < 25 in quadrant 2; 2+ growth:
≥ 25 CFUs in quadrant 2 and < 25 in quadrant 3; 3+
growth: ≥ 2 5C F U si nq u a d r a n t3a n d<2 5i nq u a d r a n t
4; and 4+ growth: ≥ 25 CFUs in quadrant 4. For statistical
analyses, we classified children into two groups: sparsely
colonized (if bacterial growth was scant, 1+, or 2+) or
densely colonized (if bacterial growth was 3+ or 4+)
with S. pneumoniae.
Statistical analysis
All statistical analyses were performed using Windows
Statistical Package for the Social Sciences, v.17.0. The
association between S. pneumoniae colonization, S. aureus
colonization, and all other variables, i.e., clinical and
epidemiological parameters of children and microbiological
characteristics of S. pneumoniae, was determined using
univariate and multivariate statistical analyses. Fisher’s
exact test was used for all univariate analyses, except when
Eur J Clin Microbiol Infect Dis (2011) 30:7–19 9the variables had more than two categories. For the latter, we
applied the Pearson’s Chi-square statistical analysis. All
statistical tests were two-tailed and p-values<0.05 were
considered to be significant. Those variables with p-values
of 0.15 or less in univariate analyses were then included in a
multivariate analysis, i.e., multiple logistic binary regression
analysis.
Results
The study population included 250 healthy children aged 2
to 5 years (average 4.43 years; median 5 years), of which
56% were female. The distribution of age was as follows:
2 years: 1 child; 3 years: 19 children; 4 years: 101 children;
and 5 years: 129 children. Of the children’s families, 6%,
84%, and 11% belonged to high, medium, or low
socioeconomic status, respectively. The clinical and demo-
graphic characteristics of the children enrolled in this study
are listed in Tables 1 and 2.
S. pneumoniae and S. aureus were isolated from 71
(28%)and141children (56%),respectively.Co-colonization
of S. pneumoniae and S. aureus was observed in 39
children (16%) (Table 1). The proportion of S. pneumoniae
colonization showed a peak at the age of 3 years (42%; n=
8/19), whereas a decrease of the prevalence among older
children was observed (4 years: 29%, n=29/101, and
5 years: 26%, n=34/129). Instead, the frequency of S. aureus
colonization scarcely varied between different age groups:
53% (10/19) among children 3 years of age, 55% (56/101)
among children 4 years of age, and 58% (75/129) among
children 5 years of age. No colonization by S. pneumoniae
nor by S. aureus was detected in the children who were
2 years of age. The univariate analysis showed that the
occurrence of colonization with S. pneumoniae or S. aureus
was not statistically different between children aged 4 years
or less versus children of age 5 years (p=0.48 and p =0 . 6 1 ,
respectively; Table 1). The highest rates of S. pneumoniae
colonization were observed among children with siblings
(32%), with siblings≤5 years old (35%), and with frequent RI
(46%). In contrast, the lowest prevalence rates were observed
among asthmatic children (21%) and among children
attending a day care center (21%) (Tables 1 and 2). However,
none of these factors were positively or negatively associated
with S. pneumoniae colonization. The highest prevalence
rates of S. aureus colonization were observed among children
living in crowding (73%) and having non-respiratory atopies
(75%), whereas the lowest prevalence rates were observed
among asthmatic children (44%) (Tables 1 and 2). However,
the occurrence of non-respiratory atopies was the only
characteristic positively associated with S. aureus colonization
(p=0.018 [univariate analysis] and p = 0.017 [multivariate
analysis], respectively; Table 1).
S. pneumoniae–S. aureus co-colonization according to
the distribution of age was as follows: 3 years 26% (5/19
children), 4 years 17% (17/101 children), and 5 years 13%
(17/129). According to the univariate analysis, the occur-
rence of S. pneumoniae–S. aureus co-colonization was not
statistically different between children aged 4 years or less
versus children 5 years of age (p=0.29; Table 1). We
observed that the proportion of S. pneumoniae–S. aureus
co-colonization was higher among children with siblings
compared to those without siblings (19% vs. 8%, respec-
tively), but lower among asthmatic children compared to
non-asthmatic children (5% vs. 18%, respectively; Tables 1
and 2). However, none of these factors were statistically
associatedwiththeS. pneumoniae–S. aureus co-colonization
using univariate or multivariate analyses.
The S. pneumoniae strains isolated in this study
displayed 16 different pneumococcal serotypes, of which
6B (14%), 19F (12%), 23F (12%), 15 (9%) 6A (8%), 11
(8%), 23A (6%), and 34 (6%) were the most common.
Serotypes 14 and 38 were found in three strains (5%) and
serotypes 6C, 9 N, 10, 18A, 20, and 23B were found in
only one strain (1%). Six percent of the strains (n=4) were
non-typeable. The serotype 6C strain did not react with any
pneumococcal antiserum during the Quellung test and it
was initially classified as non-typeable. However, we did
detect the wciN6C gene by PCR in this strain, and the 6C
capsular type was confirmed using 6C-specific monoclonal
anticapsule antibodies.
In total, 28 out of the 65S. pneumoniae strains (43%)
displayed vaccine serotypes. The prevalence of colonization
of S. pneumoniae vaccine serotypes and the clinical
demographic characteristics are given in the Table 3.W e
observed that children with a previous RI were less often
colonized by vaccine serotypes than children without
previous RI (18% vs. 52%, respectively). According to
the univariate, but not to the multivariate, analysis, having a
previous RI was a factor inversely associated with vaccine
serotype colonization (p=0.02 and p = 0.057, respectively).
We observed no differences in the proportion of S.
pneumoniae isolated from children colonized or not
colonized with S. aureus (28% vs. 29%, respectively, p=
0.77; Table 1). Likewise, we observed no differences in the
proportion of S. aureus isolated from children colonized or
not colonized with S. pneumoniae (55% vs. 57%, respec-
tively, p = 0.77; Table 1). However, the proportion of S.
aureus isolated among children colonized with vaccine
serotypes was nearly two-fold lower than among children
colonized with non-vaccine serotypes (36% vs. 68%,
respectively). Likewise, we observed that the proportion
of vaccine serotypes isolated among children colonized
with S. aureus was two-fold lower than among children
non-colonized with S. aureus (29% vs.60%, respectively).
The univariate analysis indicated that the colonization with
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12 Eur J Clin Microbiol Infect Dis (2011) 30:7–19S. pneumoniae vaccine serotypes was negatively associated
with S. aureus colonization (p=0.013; Table 3). This
negative relationship remained significant after the multi-
variate analysis (p=0.03; Table 3). In other words, in
particular, the vaccine-type pneumococci were a risk factor
for S. aureus colonization and vice versa.
Colonization with S. pneumoniae was dense in 23% (n=
16) and sparse in 77% (n=55) of the 71 children with positive
cultures (Table 4). A dense colonization by S. pneumoniae
was frequently seen among children with a low socio-
economic status (56%), attending day care centers (50%),
with siblings≤5 years old (35%), and with a previous RI (39%)
Table 3 Prevalence of S. pneumoniae vaccine serotypes colonization according to the clinical demographic characteristics
Characteristics S. pneumoniae
isolated strains
S. pneumoniae
serotyped strains
Vaccine serotypes
nn n (%)
a UA MA
Total 71 65 28 (43) OR (CI 95%) pp
Sex Male 31 29 16 (55) 0.4 (0.1–1.1) 0.08 0.07
Female 40 36 12 (33)
Siblings Yes 56 52 21 (40) 0.5 (0.1–1.9) 0.53
No 15 13 7 (54)
Siblings≤5 years Yes 26 24 10 (42) 1.1 (0.3–3.3) 1.00
No 30 28 11 (39)
Day care center Yes 6 6 2 (33) 0.6 (0.1–3.7) 0.69
No 65 59 26 (44)
Crowding Yes 7 6 4 (67) 2.8 (0.4–16.7) 0.39
No 63 58 24 (41)
Smoker at home Yes 29 27 13 (48) 1.4 (0.5–3.8) 0.61
No 42 38 15 (39)
Atopies Yes 27 24 11 (46) 1.1 (0.4–3.2) 0.79
No 44 41 17 (41)
Rhinitis Yes 13 12 5 (42) 0.9 (0.2–3.3) 1.00
No 58 53 23 (43)
Asthma Yes 8 8 5 (63) 2.4 (0.5–11.3) 0.27
No 63 57 23 (40)
Non-respiratory atopies Yes 12 10 5 (50) 1.3 (0.3–5.3) 0.73
No 59 55 23 (42)
Previous RI Yes 18 17 3 (18) 0.1 (0.0–0.7) 0.02* 0.057
No 53 48 25 (52)
Frequent RI Yes 6 5 3 (60) 2.1 (0.3–13.5) 0.64
No 65 60 25 (42)
Previously hospitalized Yes 20 18 11 (61) 2.7 (0.9–8.4) 0.09 0.11
No 51 47 17 (36)
Previous antibiotic use Yes 23 21 11 (52) 1.7 (0.6–4.9) 0.42
No 48 44 17 (39)
S. aureus colonization Yes 39 35 10 (29) 0.2 (0.0–0.7) 0.013* 0.03*
No 32 30 18 (60)
SE High 5 4 4 (100) NA 0.048
b 0.61
Medium 57 53 20 (38)
Low 9 8 4 (50)
CI: confidence interval; OR: odds ratio; RI: respiratory infection; SE: socioeconomic status; NA: not applicable; UA: univariate analysis (Fisher’s
exact test); MA:multivariate analysis (logistic binary regression analysis)
aPercentages were calculated on the basis of the 65 S. pneumoniae strains available for serotyping
bPearson’s Chi-square statistic univariate analysis
*Significance: α = 0.05
Eur J Clin Microbiol Infect Dis (2011) 30:7–19 13Table 4 Colonization density of S. pneumoniae and clinical and demographic characteristics of the 71 colonized children
Characteristics N Colonization OR (CI 95%) UA MA
Sparse bacterial growth
(scant, 1+, or 2+)
Dense bacterial growth
(3+ or 4+)
n (%) n (%) pp
Total 71 55 (77) 16 (23)
Sex Male 31 26( 84) 5 (16) 0.5 (0.1–1.6) 0.39
Female 40 29 (73) 11(28)
Siblings Yes 56 44 (79) 12 (21) 1.3 (0.3–4.9) 0.73
No 15 11 (73) 4 (27)
Siblings≤5 years: Yes 26 17 (65) 9 (35) 0.2 (0.0–0.8) 0.047* 0.02*
No 30 27(90) 3 (10)
Day care center Yes 6 3 (50) 3 (50) 0.2 (0.0–1.3) 0.12 0.07
No 65 52(80) 13 (20)
Crowding Yes 7 5 (71) 2 (29) 0.7 (0.1–4.0) 0.65
No 63 50(79) 14 (22)
Smoker at home Yes 29 22 (76) 7 (24) 0.8 (0.2–2.6) 0.78
No 42 33 (79) 9 (21)
Atopies Yes 27 22 (81) 5 (19) 1.4 (0.4–4.8) 0.57
No 44 33 (75) 11 (25)
Rhinitis Yes 13 10 (77) 3 (23) 0.9 (0.2–4.0) 1.00
No 58 45(77) 13 (22)
Asthma Yes 8 5 (63) 3 (38) 0.4 (0.0–2.0) 0.36
No 63 50 (79) 13(21)
Non-respiratory atopies Yes 12 12 (100) 0 (0) 0.7 (0.6–0.8) 0.056 0.99
No 59 43 (73) 16 (27)
Previous RI Yes 18 11 (61) 7 (39) 0.3 (0.0–1.0) 0.09 0.47
No 53 44 (83) 9 (17)
Frequent RI Yes 6 6 (100) 0 (0) 1.3 (1.1–1.5) 0.32
No 65 49 (75) 16 (25)
Previously hospitalized Yes 20 17 (85) 3 (15) 1.9 (0.4–7.7) 0.52
No 51 38 (75) 13 (25)
Previous antibiotic use Yes 23 18 (78) 5 (22) 1.0 (0.3–3.5) 1.00
No 48 37 (77) 11 (23)
S. aureus colonization Yes 39 30 (77) 9 (23) 0.9 (0.3–2.8) 1.00
No 32 25 (78) 7 (22)
Vaccine serotypes Yes 28
a 25 (89)
a 3 (11) 3.5 (0.8–14.1) 0.07 0.31
No 37
a 26 (70)
a 11 (30)
SE High 5 5 (100) 0 (0) NA 0.02
b* 0.42
Medium 57 46 (81) 11 (19)
Low 9 4 (44) 5 (56)
CI: confidence interval; OR: odds ratio; RI: respiratory infection; SE: socioeconomic status; UA: univariate analysis (Fisher’s exact test); MA:
multivariate analysis(logistic binary regression analysis)
aNumbers and percentages are based on the 65 S. pneumoniae strains available for serotyping
bPearson’s Chi-square statisticunivariate analysis
*Significance: α = 0.05
14 Eur J Clin Microbiol Infect Dis (2011) 30:7–19(Table 4). In contrast, children with non-respiratory atopies
and with a high socioeconomic status were invariably sparsely
colonized. According to the univariate analyses, children
with siblings ≤ 5 years old and a low socioeconomic status
were more densely colonized with S. pneumoniae (p=0.047
and p=0.02, respectively; Table 4). According to multivariate
analyses, only having siblings≤5 years old remained a factor
positively associated with dense pneumococcal colonization
(p=0.02; Table 4).
The prevalence of antimicrobial non-susceptibilityamong
S. pneumoniae strains was as follows: trimethoprim–
sulfamethoxazole 40%, erythromycin 38%, penicillin 34%
(intermediate 20% and high level 14%), tetracycline 34%,
clindamycin 29%, cefuroxime 15%, meropenem 15%,
chloramphenicol 9%, and ceftriaxone 5% (Table 5). Resis-
tance to cefotaxime, cefepime, and ertapenem was observed
in 2% of the strains. We found no S. pneumoniae strains
showingresistancetodaptomycin,levofloxacin,moxifloxacin,
linezolid, telithromycin, or vancomycin. Thirty-five percent of
the S. pneumoniae strains (n=23) were MDR (Table 5).
The serotypes observed among the 22 penicillin-non-
susceptible S. pneumoniae (PNSP) strains were 6B (40.9%;
n=9),23F(22.7%;n=5), 6A (9.0%; n=2), 19F (9.0%; n =2 ) ,
and 14 (4.5%; n=1). The serotypes among the 23 MDR
strains were 6B (39%; n=9), 23F (22%; n=5), 14 (13%;
n=3), 23A (13%; n = 3), and 19F (4%; n=1). Interestingly,
14% (n=3) of the PNSP and 9% (n=2) of the MDR strains
were non-typeable. Overall, the prevalence of non-
susceptibility to any of the antimicrobials tested and of
multidrug resistance was significantly increased among strains
belonging to vaccine serotypes compared to strains belonging
to non-vaccine serotypes (p-values<0.001; Table 5).
Risk factors for colonization with trimethoprim–
sulfamethoxazole- or tetracycline-non-susceptible strains
were allergies [p=0.03; OR (CI 95%) 3.38 (1.1–9.7)] and
having siblings [p=0.003; OR (CI 95%) 0.13 (0.0–0.5)],
respectively (data not shown). We found no clinical or
demographic characteristics associated with non-susceptibility
to any other antimicrobial drug studied. Interestingly, we
observed a significant relationship between trimethoprim–
sulfamethoxazole non-susceptibility or multidrug resistance
and S. pneumoniae colonization density. The vast majority of
the trimethoprim–sulfamethoxazole-non-susceptible or MDR
S. pneumoniae strains colonized children sparsely (92%, p=
0.03, and 96%, p=0.01, respectively; Table 5).
Discussion
The prevalence of S. pneumoniae colonization reported in
different parts of the world varies widely. This likely
reflects both variation in study populations with respect to
age, ethnicity, and socioeconomic conditions, as well as
differences in sampling and isolation techniques. Moreover,
the distribution of serotypes is temporal and varies by
geographic location [2–4]. In the current study, we
observed a pneumococcal colonization prevalence of 28%
in Merida, Venezuela. In 2000, we studied a group of 125
healthy children under 5 years old from the same city, and
we observed a similar colonization prevalence, i.e., 24%
[19]. Previous studies performed in Latin America among
healthy children in the same age group have shown
significant differences of at least 37% in the prevalence of
S. pneumoniae colonization, e.g., 21.4% in Mexico, 35.8%
in Brazil, 41% and 48.3% in Peru, and 59.1% in Guatemala
[25–28].
In the current study, serotypes 6B, 19F, 23F, 15, 6A, 11,
23A, and 34 were observed most frequently, accounting for
75% of all isolates. Except for serotype 34, these serotypes
have also been described as the most common serotypes
colonizing children in other Latin American countries.
Serotype 34 hasbeen observed to colonize Peruvian children,
albeit in a low proportion [19, 25–28]. Of the S. pneumoniae
strains isolated in our study, 51% showed serotypes causing
invasive diseases in Venezuela and 18 other Latin American
countries [29]. We also observed one strain belonging to the
recently described serotype 6C, which has not been reported
previously among carriers in Latin America. Although we
did not isolate strains belonging to the heptavalent conjugate
vaccine serotypes 4, 9 V, and 18C, the other four serotypes
included in this vaccine, i.e., 6B, 14, 19F, and 23F, were
displayed by 43% of the strains. The distribution of
serotypes among children in Venezuela has been previously
described among the population of Warao Amerindians.
This study revealed a comparable distribution of serotypes
and frequency of vaccine serotypes [30]. Considering that
the pneumococcal vaccine is not included in the vaccination
schedule for healthy Venezuelan children, our study pro-
vides relevant information that will be useful for future
monitoring of the effect of pneumococcal vaccination on the
prevalence of colonization and the distribution of serotypes
in this community.
Variousclinicalanddemographic characteristics havebeen
described to be associated with an increase in S. pneumoniae
colonization, such as ethnicity, crowding, family size,
siblings, smoking (passive and active), recent antibiotic
use, and low income of the parents [4, 31], but none of
those factors were found to be associated with nasal S.
pneumoniae colonization in our study. However, our semi-
quantitative measurement of the density of colonization with
S. pneumoniae showed that children with siblings≤5y e a r s
old were more densely colonized with S. pneumoniae.T h i s
is of great relevance, because exposure to other children
during childhood, especially to younger siblings, has been
clearly associated with an increased risk for invasive pneumo-
coccal disease [31]. We also observed that colonization with
Eur J Clin Microbiol Infect Dis (2011) 30:7–19 15S. pneumoniae was progressively becoming denser as
socioeconomic status decreased. We suspect that the combi-
nation of dense colonization and low socioeconomic status
puts these children at increased risk to develop pneumococcal
disease compared to the general population. In line with this,
episodes of chronic otitis media with effusion have been
related to an increased nasopharyngeal colonization density
of S. pneumoniae [5], and several outbreaks of pneumococcal
disease have occurred in communities suffering from poverty
and malnutrition [32, 33]. Hence, pneumococcal conjugate
vaccination is imperative in these groups of children.
Although day care center attendance has been associated
with an increased risk for S. pneumoniae colonization [4],
in our study, day care center attendees did not show an
increased density of colonization nor an increased coloni-
zation rate. These findings might be explained by the low
number of day care center attendees (11%) present in our
study, which affects the statistical power.
Within the past three decades, resistanceof S. pneumoniae
to β-lactams, macrolides, and other antimicrobial classes
has escalated dramatically throughout the world. Great
variation in the rates of resistant S. pneumoniae isolates from
carriers have been observed between continents, countries,
and even regions [6]. In most of the studies performed in
Latin American children, resistance analysis was restricted
to penicillin, and only in a few studies were trimethoprim–
sulfamethoxazole, erythromycin, chloramphenicol, and
clindamycin investigated [6, 25–28, 34, 35]. In our study,
resistance to trimethoprim–sulfamethoxazole was predomi-
nant (40%), comparable to other Latin American countries
where the resistance rates varied from 42% in Brazil [34]t o
73% in Peru [27]. The prevalence of penicillin resistance
has been reported to vary widely, for instance, ranging from
1.4% in the North region of Brazil to 49.0% in Fortaleza [6].
Likewise, high-level penicillin-resistance rates (≥ 2 μg/ml)
ranged from 0% in certain regions of Brazil to 8% in Chile,
but reached the exceptionally high rate of 38.8% observed
among pneumococci colonizing children in Santa Fé,
Argentina [6]. In our study, we observed alarmingly higher
prevalence rates of penicillin- (34%) and high-level
Table 5 Frequency of antimicrobial resistance among S. pneumoniae strains according to vaccine serotypes and colonization density
Antimicrobial Strains, total Serotypes OR (95% CI)
a p Colonization density OR (95% CI)
a p
Vaccine:
n=28
Non-vaccine:
n=37
Dense:
n=14
Sparse:
n=51
n % n (%) n (%) n (%) n (%)
T/S NS 26 40 17 (65) 9 (35) 4.8 (1.6–13.9) 0.005** 2 (8) 24 (92) 5.3 (1.0–26.2) 0.03*
S3 9 1 1 2 8 1 2 2 7
Erythromycin NS 25 38 20 (80) 5 (20) 16.0 (4.5–55.8) 0.000** 2 (8) 23 (92) 4.9 (1.0–24.2) 0.06
S 40 8 32 12 28
PNSP NS 22 34 17 (77) 5 (23) 9.8 (2.9–33.1) 0.000** 4 (18) 18 (82) 1.3 (0.3–4.9) 0.75
S4 3 1 1 3 2 1 0 3 3
Tetracycline NS 21 34 15 (71) 6 (29) 5.9 (1.8–18.7) 0.003** 2 (10) 19 (90) 3.5 (0.7–17.6) 0.12
S4 4 1 3 3 1 1 2 3 2
Clindamycin NS 19 29 16 (84) 3 (16) 15.1 (3.7–61.1) 0.000** 1 (5) 18 (95) 7.0 (0.8–58.6) 0.049
S4 6 1 2 3 4 1 3 3 3
Cefuroxime NS 11 15 11 (100) 0 (0) 3.1 (2.1–4.7) 0.000** 1 (9) 10 (91) 3.1 (0.3–27.1) 0.43
S5 4 1 7 3 7 1 3 4 1
Meropenem NS 10 15 10 (100) 0 (0) 3.0 (2.0–4.4) 0.000** 1 (10) 9 (90) 2.7 (0.3–24.0) 0.67
S5 5 1 8 3 7 1 3 4 2
Chloramphenicol NS 6 9 6 (100) 0 (0) 2.0 (1.9–3.7) 0.005** 0 (0) 6 (6) 1.3 (1.1–1.5) 0.32
S5 9 2 2 3 7 1 4 4 5
MDR 23 35 18 (78) 5 (2) 11.5 (3.4–38.9) 0.0001** 1 (4) 22 (96) 9.8 (1.1–81.1) 0.01*
Non-MDR 42 10 32 13 29
CI: confidence interval; OR: odds ratio; T/S: trimethoprim–sulfamethoxazole; PNSP: penicillin-non-susceptible S. pneumoniae; NS: non-
susceptible; S: susceptible; MDR: multidrug-resistant
aUnivariate analysis(Fisher’s exact test)
*Significance: α = 0.05
**Significance: α = 0.01
16 Eur J Clin Microbiol Infect Dis (2011) 30:7–19penicillin-resistant strains (14%) than those reported in most
of the South American countries.
The described rates of non-susceptibility to other anti-
microbials in Latin America also show a wide range:
erythromycin from 7% in Peru [25] to 38% in Mexico
[35]; clindamycin from 7% in Peru [27] to 18% in Brazil
[34]; chloramphenicol from 0% in Mexico [28] to 27% in
Peru [27]; and multidrug resistance from 3% in Peru [27]t o
20% in Guatemala [26]. Our results demonstrate one of the
highest resistance rates against erythromycin (38%), clin-
damycin (29%), and multidrugs (35%) among pneumococci
colonizing healthy children in Latin American countries.
The highest global resistance is observed in those
countries with easy access to antibiotics, such as Venezuela.
Due to the continuous exposure of bacteria to antimicrobials,
the selection of resistant strains occurs [7, 36]. Colonized
children play an important role in the transmission of
antibiotic-resistant pneumococcal strains within the com-
munity. Vaccination of children significantly reduces
carriage and disease caused by antibiotic-resistant pneumo-
cocci in this population, as well as in unvaccinated children
and adults due to herd immunity [36]. Our findings
demonstrate a high prevalence of antimicrobial resistance
among pneumococcal strains. Future efforts should be
made to reduce the carriage and transmission of these
strains, firstly by starting an appropriate pneumococcal
vaccination program, and secondly by the substantial
reduction of antimicrobial use and the use of antimicrobials
that exert less selection pressure. These strategies will have
thebestimpactonthecontrolofpneumococcal antimicrobial
resistance in the Venezuelan community [7, 36].
Trimethoprim–sulfamethoxazole-non-susceptible or MDR
pneumococcal strains colonized children in a significantly
less dense manner. Although antimicrobial resistance offers
obvious advantages to bacteria, disadvantages such as a
reduced virulence or viability might co-occur. In line with
this, a lower prevalence of S. pneumoniae penicillin- or
cephalosporin-resistant strains among isolates from blood or
cerebrospinal fluid has been reported, explained by loss of
fitness due to the acquisition of resistance [7]. We, therefore,
hypothesize that certain trimethoprim–sulfamethoxazole-
non-susceptible or MDR pneumococcal isolates may have
a reduced ability to produce a dense nasal colonization due
to a reduced ability to proliferate in the nasal mucosa.
Toourknowledge,thisstudyisthefirstassessmentofnasal
S. aureus colonization in healthy children in Venezuela.
Recently, several studies have been conducted in Latin
America to investigate the prevalence of S. aureus nasal
colonization among healthy children. In children aged
2 months to 5 years attending day care centers in Brazil,
and in Mexican children aged 6 months to 6 years, the
prevalence of S. aureus colonization was 31.1% and 10.1%,
respectively [37, 38]. Interestingly, while these rates were
similar to those reported in other countries, such as Turkey
(28.4%) and the USA (25.6%) [39, 40], the prevalence of
S. aureus among Venezuelan children was much higher
(56%).
With respect to risk factors, particular demographic
characteristics have been related to nasal S. aureus coloniza-
tion in children. For instance, in Brazilian children and in
Turkish children, family size and educational level of the
parents were associated with the prevalence of S. aureus
nasal colonization [37, 39]. In addition, age, sex, and
ethnicity were associated with nasal S. aureus colonization
in the USA [40]. In our study, we found none of these
demographic factors to be associated with S. aureus
colonization.
Although an increase of S. aureus colonization among
children with respiratory and non-respiratory allergies has
been reported [11, 12], we observed no statistical differences
in the prevalence of S. aureus colonization between children
with asthma or rhinitis and children without these respira-
tory allergies. Instead, the only clinical characteristic
positively associated with S. aureus colonization was non-
respiratory atopic disease. Similarly, several studies have
also shown increased S. aureus nasal colonization among
patients with atopic dermatitis compared to the general
population [11, 41]. Super-antigens and toxins of S. aureus
have been implicated as environmental factors in the
pathogenesis of atopic dermatitis [41].
The only characteristic in our study that was negatively
associated with S. aureus colonization was the nasal
colonization by pneumococcal vaccine serotypes. Similar
observations have been made for Dutch children aged 1–
19 years, for Israeli children aged 40 months or younger,
a ndf o rS o u t hA f ri c a nch i l dr e nag e d1 –60months[10, 16, 17].
It has been suggested that bacterial interference orchestrated
by the host immune system might explain the inverse relation
between S. aureus and S. pneumoniae [42, 43]. Our results
demonstrate, for the first time, the negative association
between these bacterial pathogens in the same niche, i.e.,
the nasal cavity. The introduction of pneumococcal conjugate
vaccination is expected to reduce the morbidity and mortality
caused by S. pneumoniae infections in our population. On the
other hand, pneumococcal conjugate vaccination might alter
the upper respiratory tract flora, and, consequently, increase
the risk of S. aureus colonization and diseases [44]. To this
respect, the development of a pneumococcal vaccine that
only protects against invasive disease without affecting
pneumococcal colonizationisaninterestingmatterofscientific
debate [44].
In summary, weobservedthathealthy Venezuelan children
with young siblings and those of a low socioeconomic status
were more densely colonized with S. pneumoniae.I n
addition, non-respiratory atopy was a risk factor for S. aureus
colonization. Furthermore, S. pneumoniae vaccine serotypes
Eur J Clin Microbiol Infect Dis (2011) 30:7–19 17were negatively associated with a previous history of RI and
with S. aureus nasal colonization. Finally, a very high
prevalence of pneumococcal multidrug-resistant strains among
carriers was detected, and trimethoprim–sulfamethoxazole-
and multidrug-resistant isolates were less densely present
during colonization. These findings highlight the importance
of the monitoring of colonization, and allow us to recommend
the introduction of pneumococcal conjugate vaccination and
to discuss the inappropriate antibiotic use in our community.
This work provides a baseline for further assessment of
epidemiological strategies aiming at the prevention and
control of pneumococcal transmission, disease, and anti-
microbial resistance.
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